NJ State Employees Deferred Compensation Plan Has $7.78 Million Stock Position in Johnson & Johnson $JNJ

NJ State Employees Deferred Compensation Plan cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 10.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 41,969 shares of the company’s stock after selling 4,730 shares during the quarter. Johnson & Johnson accounts for 0.9% of NJ State Employees Deferred Compensation Plan’s portfolio, making the stock its 14th largest position. NJ State Employees Deferred Compensation Plan’s holdings in Johnson & Johnson were worth $7,782,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Abich Financial Wealth Management LLC purchased a new position in Johnson & Johnson during the third quarter valued at approximately $26,000. Evolution Wealth Management Inc. acquired a new stake in Johnson & Johnson during the second quarter valued at $27,000. Clayton Financial Group LLC acquired a new position in Johnson & Johnson in the 3rd quarter worth about $28,000. Semmax Financial Advisors Inc. grew its stake in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after buying an additional 72 shares in the last quarter. Finally, Compass Financial Services Inc lifted its stake in Johnson & Johnson by 707.1% in the third quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock valued at $42,000 after acquiring an additional 198 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the subject of a number of recent research reports. Barclays upped their price objective on shares of Johnson & Johnson from $197.00 to $217.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 30th. BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Royal Bank Of Canada upped their target price on Johnson & Johnson from $240.00 to $255.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 3rd. HSBC lifted their price target on shares of Johnson & Johnson from $240.00 to $265.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Finally, Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $233.73.

Johnson & Johnson Stock Down 0.5%

NYSE JNJ opened at $243.37 on Tuesday. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $246.35. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. The stock has a market cap of $586.51 billion, a PE ratio of 22.02, a PEG ratio of 2.36 and a beta of 0.35. The firm has a 50-day simple moving average of $218.09 and a 200 day simple moving average of $197.35.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The company had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. On average, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 47.06%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.